NextCure (NASDAQ:NXTC) Posts Earnings Results, Misses Expectations By $0.39 EPS

NextCure (NASDAQ:NXTC) posted its earnings results on Tuesday. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.39), FiscalAI reports.

NextCure Trading Down 4.6%

NXTC stock traded down $0.29 during mid-day trading on Tuesday, reaching $5.98. The company’s stock had a trading volume of 81,522 shares, compared to its average volume of 673,259. The stock has a market cap of $21.59 million, a PE ratio of -0.69 and a beta of 1.22. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The company’s 50 day moving average is $6.06 and its two-hundred day moving average is $7.67.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc bought 5,626 shares of the stock in a transaction dated Friday, October 23rd. The shares were acquired at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the acquisition, the insider directly owned 728,045 shares in the company, valued at approximately $3,516,457.35. This trade represents a 0.78% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have purchased 15,537 shares of company stock valued at $77,603. Company insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. HC Wainwright reissued a “buy” rating on shares of NextCure in a report on Thursday, August 13th. Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 26th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.00.

About NextCure

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.